Introduction and Aims:
The expression of epithelial to mesenchymal transition (EMT) markers is a reliable predictor of the progression towards interstitial fibrosis and tubular atrophy of the renal grafts. In vitro experiments suggest that calcineurin inhibitors (CNI) can induce EMT of tubular epithelial cells. Although no evidence was ever provided in vivo, this suggests that EMT could be involved in the pathogenesis of renal fibrosis induced by CNI. Methods: We have previously reported the results of a prospective randomized trial comparing the elimination at month 3 of either cyclosporine (CsA, n=54) or mycophenolate (MMF, n=54) from a triple drug regimen in 108 de novo renal transplant patients. All of them had 2 systematic graft biopsies at months 3 and 12 post engraftment. In the leftover material, we retrospectively detected in tubular cells and by immuno-histochemistry the expression of two validated markers of EMT: the de novo expression of vimentin (Vim) and the cytoplasmic translocation of b-catenin (Cat). Results: We were able to measure the EMT score at both months 3 and 12 in a total of 68 patients (34 in each group). In the CsA group, the Vim and Cat scores had progressed between 3 and 12 months from 1.530.86 to 1.990.97 (p=0.004) and 1.550.79 to 1.881.04 (p=0.041), respectively, while they remained stable in the MMF group. Remarkably, the 3-month EMT scores were correlated with the 1-year eGFR and the Chronic Allograft Damage Index. Since acute cellular rejection (ACR) may trigger EMT, we performed a subgroup analysis and excluded the 10 patients who had presented an ACR (CsA group, n=2; MMF group, n=8). Vim and Cat scores respectively progressed from 1.550.86 to 2.00.98 (p=0.007) and from 1.570.79 to 1.891.06 (p=0.065) under CsA, but, strikingly, these scores decreased in patients under MMF and without CsA : Vim from 1.670.92 to 1.380.91 (p=0.13) and Cat from 1.600.85 to 1.260.84 (p=0.047) . Conclusions: First, we confirm that the early expression of EMT markers is of bad prognostic value regarding graft function and histology. Moreover, we found that the EMT score is durably influenced by CsA: maintenance of CsA increases the EMT score, while disruption of CsA attenuates it, as long as the patients dont experience rejection. Thus, in renal grafts, CsA induced fibrosis might involve EMT.
Wegener's granulomatosis and microscopic polyangiitis are ANCA associated vasculitides (AAV) with significant morbidity and mortality. Reports suggest that patients with AAV are at increased risk of malignancies and cardiovascular morbidity and mortality. Methods: Long-term outcome data on patients of four randomised controlled trials in new onset systemic AAV were collected. The trials included 1 in early systemic vasculitis (NORAM), 2 in patients with mild to moderate renal impairment (CYCAZAREM, CYCLOPS) and 1 in patients with severe renal impairment (MEPEX). A questionnaire was send to the participating physicians and data on survival, renal survival, relapse rate, immunosuppressive therapy, cancer rate, bone fractures and cardiovascular morbidity recorded. Results: Returns were received from 469 (87.3%) of 537 patients in the original trials. The median duration of follow up was 5.4 years (range 0 to 11.7). There were 132 (28.1%) deaths. The survival at 1, 5 and 10 years were 83.9%, 72.9% and 63.3%. 87 (18.6%) patients required renal replacement therapy. Renal survival at 1, 5 and 10 years was 87.1%, 82.3% and 79.8%. There were 62 new diagnoses of malignant conditions in 52 (11.1%) patients. Of these 31 were solid organ cancers, 9 haematological malignancies and 22 skin cancers. Within 5 years of enrolment 35 (7.6%) patients had a myocardial infarction, 22 (4.8%) a cerebro-vascular accident and 27 (5.9%) a thrombo-embolic event. In addition 38 (8.3%) suffered a bone fracture and 136 (29.6%) developed an infection requiring hospitalisation. Conclusions: Preliminary analysis suggests that patients with AAV are at increased risk of developing malignant diseases and cardio-vascular events. In addition they suffer a high rate of fractures and severe infections. Introduction and Aims: Idiopathic IgA Nephropathy (IgAN), the most common biopsy-proven glomerulonephritis worldwide, is characterized by asymptomatic microscopic hematuria (mH) with or without proteinuria or by recurrent episodes of macroscopic hematuria which usually occur in concomitance with mucosal infections of upper respiratory tract or other infections; 30% of patients develop progressive renal failure. Although several investigators have focused on the identification of specific genetic markers associated with the development and progression of this common disease, the genomic and transcriptomic involvement is still not completely defined. Methods: To this purpose, we measured the intracellular RNA expression level of approximately 15.000 genes, using oligonucleotide microarray chips (HG-U133A, Affymetrix), isolated from whole blood. A large cohort of well characterized IgAN patients [n=16 IgAN patients with persistent mH and normal renal function (IgAN/NORM), n=6 IgAN patients with persistent mH and deteriorated renal function (IgAN/DRF)], and n=7 polycystic kidney disease patients with chronic renal failure (PKD) were included in the study and eight healthy subjects were used as controls (HS). Additionally, in order to identify genes differentially regulated during the acute phase of the disease, we analyzed the genomic profile of 3 patients included in IgAN/NORM group during mH and at the time of the macrohematuria (MH) episode. Results: Several statistical methods identified 7 genes able to discriminate IgAN/NORM patients from HS (FDR = 43%, P < 0.0005), 9 genes highly discriminating IgAN/NORM from IgAN/DRF patients (FDR = 24%, P < 0.0005). No genes reached statistical significance in the comparison between IgAN/DRF and PKD patients (FDR>90%). Data analysis showed that genes differentially expressed between IgAN/NORM versus HS were primarily involved in WNT and PI3K/AKT pathways, while those differentiating IgAN/NORM versus IgAN/DRF were implicated in regulatory mechanisms involved in the balance between cell proliferation and apoptosis. Interestingly, when we analyzed the genomic changes occurring during the MH episodes, we found 62 up-regulated (p>0.0001) and 65 downregulated (p>0.0001) genes, respectively, compared to the mH status. These genes represent key elements of important biological processes, such as interferon signaling (e.g., IFIT3, MX1), ubiquitin (e.g. UBE2L6) and immune proteasome (e.g. PSMB8) pathway.
SO007 SPECIFIC GENOMIC FINGERPRINTS ARE HIGHLY ASSOCIATED TO THE ONSET AND DEVELOPMENT OF IDIOPATHIC IgA NEPHROPATHY

Conclusions:
The above innovative high-throughput methodology has shown, for the first time, unlighted biological mechanisms possibly involved in the complex machinery associated to the development and progression of IgAN. In addition, these data may indicate potential targets for screening, prevention and early diagnosis of the disease and more appropriate and effective treatment.
Introduction and Aims: High-dose chemotherapy followed by peripheral blood autologous stem cell transplantation (ASCT) is presently considered the most effective treatment for AL amyloidosis. Because of the toxicity associated with such therapy, there has been concern about its utility in patients with renal failure and it has been suggested that AL amyloidosis patients with renal involvement are not ideal candidates for myeloablative chemotherapy regimens because of high morbidity and mortality rates. Methods: We here report our experience with ASCT treating 9 AL amyloidosis patients affected by moderate to severe renal insufficiency and describe the efficacy, the tolerability and the impact on renal involvement of this treatment. The median age of the patients was 50 yrs (4 M/5 F) and monoclonal protein was lambda in 8 cases and kappa in 1 case. Mean serum creatinine level at presentation was 2.7 mg/dl (range 1.6-9 mg/dl); one patient required chronic hemodialysis since the diagnosis of AL amyloidosis was made. Renal amyloidosis was documented by renal biopsy in all patients and proteinuria was nephrotic in all cases. Results: Two patients presented cardiac involvement. Seven of 9 patients (77.7%) had a haematological complete response following treatment. Out of the 2 non responder patients: one died and the other is still alive on dialysis, respectively after 8 and 17 months from ASCT. Transplant-related toxicity included grade 2-3 oral mucositis in 3 patients and veno-occlusive disease in 1 patient. The mean follow-up period of the 7 responder still alive patients was 31.2 months. Renal function (GFR) improved from mean 37.4 to mean 74.4 ml/min in all of these cases except 2: one is on chronic hemodialysis and the other presented a severe but stabilized renal failure. Proteinuria decreased from nephrotic levels to less than 0.5 g/24h after over 1 year in 5 patients. One of these patients underwent a second renal biopsy which documented the persistence of glomerular amyloid deposits despite complete remission of proteinuria. Conclusions: We conclude that ASCT for patients with renal amyloidosis, including those with renal failure, is feasible, tolerable and effective. It results in significant palliation and an improvement in quality of life, particularly in those who achieve a haematological complete response. Despite complete remission of proteinuria, glomerular amyloid deposits did not regress; a mechanism other than the amyloid mass per se seems to be responsible for the improvement of proteinuria. Introduction and Aims: ANCA-associated vasculitis, such as microscopic polyangiitis (MPA), Wegener's granulomatosis (WG) and renal limited vasculitis (RLV) are rare diseases characterized by a rapidly progressive deterioration of renal function with need of dialysis. We investigated the role of PEX in the achievement of renal recovery comparing no PEX (PEX-) and PEX (PEX+) for early dialysis-dependent patients.
SO009
CHANCES OF DIALYSIS INDEPENDENCE AFTER PLASMAEXCHANGE IN RENAL ANCA ASSOCIATED VASCULITIS
Introduction and Aims:
We recently published (JASN 2007; 18:1880-8) the results of an EC Biomedicine and Health Research, double-blind trial involving 23 Centers in Europe, which reported the effect of an Angiotensin converting enzyme inhibitor (ACE-I) in children and young people with IgA Nephropathy (IgAN), proteinuria >1g<3.5 g/day/1.73m 2 and creatinine clearance (CrCl) >50ml/min/1.73m 2 . A significant effect of ACE-I was observed for a combined end-point of >30% decrease of CrCl or worsening of proteinuria until ≥3.5g/day/1.73m 2 . We are now investigating in greater detail the modification in proteinuria in both treated and placebo patients, looking for its predictive value for final outcome. Methods: The IgACE trial investigated sixty-six patients, 20.5 (9 -35) years old, randomized to Benazepril, 0.2 mg/kg/day (ACE-I) or placebo (PL) and followed in median for 38 months. The secondary endpoint was a stable proteinuria remission (<0.5g/day/1.73m
2 ) which was observed in 13/23 (56.5%) ACE-I pts vs 3/34 (8.8%) in PL (P=0.033). Univariate and multivariate COX regression analysis were performed using categorical and continuous values of proteinuria during the whole follow-up. Results: Among the treated subjects a mean proteinuria reduction of 40% from baseline was observed. None of them worsened to nephrotic range proteinuria, and the only subject who reached the end point in this group had 30% increase in CrCl. In the placebo group, 7 patients reached nephrotic range proteinuria. COX regression analysis demonstrated that proteinuria reduction at 12 months was an early predictor of final positive outcome (survival to the combined end point) either when considered as continuous variable [ In conclusion, proteinuria modification at 12 months of follow-up in the IgACE trial proved an early predictor of final outcome both in the case of at least a 30% reduction (predicting stable remission), and in case a 30% increase (predicting progression to the combined end-point). Introduction and Aims: Autosomal dominant polycystic kidney disease (PKD) has been shown to result from loss-of-function mutations of polycystin-1 and polycystin-2. However, the mechanism by which mutations in these genes cause PKD are unknown. It has been shown that tubular epithelial cells of cystic epithelia present an increased proliferation coupled with a reduced apoptosis and an increased expression of growth factors and their receptors. In addition, cells of cystic epithelia maintain embryonic characteristics. Studies on renal stem cells (SC) , that represent the long-term cell population sustaining turn over of tubular epithelial cells, are not available in PKD. We hypothesize that an altered terminal differentiation of PKD-SC leads to increased proliferation and to the maintenance of embryonic phenotype and is involved in cystogenesis. We recently isolated a CD133+ SC population in normal human adult kidney. These cells showed clonogenic and self-renewal ability (Bussolati et al, Am J Pathol 2005) . The aim of this work was to isolate and characterize at a phenotypic and functional level SC from PKD patients, to study the differentiative ability of PKD-derived SC in respect to normal renal SC in vitro and in vivo. Methods: PKD-SC were isolated from the kidney of 6 patients with PKD, by culture in serum free medium with 1x Insulin-transferrin-selenium, 10-6 M hydrocortisone, 10ng/ml EGF and 2% FCS. PKD-SC cell lines were analyzed by cytofluorimetric analysis and RT-PCR for the expression of stem cell markers and of the renal embryonic markers HOX and Pax-2, in comparison with normal renal SC lines. Growth, clonal ability, resistance to apoptosis were evaluated. Epithelial differentiation of normal SC was evaluated in the presence of FGF-4 and HGF. A murine model of cystogenesis was obtained by implantation of undifferentiated PKD-derived CD133+ renal SC within Matrigel subcutaneously into SCID mice. At day 10, mice were sacrificed and Matrigel plugs recovered and analyzed. Results: Six different CD133+ cell population were isolated from autosomal polycystic kidneys. Comparing to the normal CD133+ SC population, these cells showed a similar morphology and expression profile but an altered differentiation potential. In particular, this population was not able to fully differentiate in epithelial and endothelial cells in vitro. Moreover, CD133+ PKD-SC cell lines showed an increased apoptosis resistance in respect to normal CD133+ SC. Moreover, when injected subcutaneously in SCID mice in Matrigel, undifferentiated PKD-derived CD133+ SC organized in cystic structures whereas normal CD133+ SC differentiated into tubular structures expressing mature epithelial markers.
Renal development
Conclusions:
The identification of alteration in the phenotypic and functional properties of resident renal SC may provide new insights in the pathogenesis of PKD. Moreover, the development of an in vivo model of human cystogenesis on SCID mice may allow to test drugs interfering Introduction and Aims: The physiopathology of cystic kidney diseases is still mysterious despite the identification of numerous genes involved. A cilia based model of cyst development recently emerged. In the way to a better understanding of cystic kidney diseases, new animals models beside mice and rats, like C. Elegans or zebrafish are used. The pronephros has been proposed to be a good model. Zebrafish mutants or morphants of genes like pkd2,invs or nephrocystin-6 are associated with dilatation of the pronephric tubule. Recently, it had been suggested, in pkd2 morphant, that dilatation is secondary to obstruction. Our aim is to confirme and understand the obstruction's origine. Methods: We used a transgenic fish expressing GFP under the control of the claudin b promotor. Thus GFP construct is expressed in the zebrafish pronephros. We injected two morpholinos to knock-down the expression of nephrocystin-6 and pkd2. We identified the zebrafish homolog of Pkdr1, the gene mutated in han:sprd rat, and we overexpressed it by RNA injection in one cell egg. We realized these experiments in duplicate. More than 60 morphants were observed in live imaging with confocal microscopy. To measure the diameter of the duct and the lumen, we achieved measurement of the distal and proximal part of the duct. We realized a stack of images, we kept the image where the diameter is the wider and made three measures. The diameter of this part of the pronephros for one fish is the mean of the three measurments. Results: We determined the normal morphology of pronephros in live, non fixed normal zebrafish. We established the normal pronephros dimensions (40 fishes) at 24 hours post fertilization (hpf), 48 hpf and 72 hpf. The diameter of the pronephros at 24 hpf is 20±2 μm and the lumen diameter is 2±1.1 μ. There is a small increase in the diameter during development. In Nephrocystin-6 and Pkd2 morphants, beside the previously described anomalies like abnormal axis or hydrocephalus, we observed that tubular dilatation begins after 36 hpf. Before, the size of the pronephros is only slighty and non significantly increased. By three days, we observed in more than 70% of morphants a huge tubular dilatation. The diameter of the proximal part of the pronephros is more the double that normaly observed, and the lumen diameter is more than ten times the normal one. The pronephros duct dilatation is extended to the 18th somites. At this part we observed the destruction of the normal tubule architecture, with disappearance of the pronephic duct lumen. We observed, only in this part of the duct, an apoptosis of the duct cells. This process is begining after 24 hpf. In the Pkdr1 overexpressing fishes we observed a tubular dilatation begining before the 24 hpf. In this case the dilatation is associated with a malformated cloaca. Conclusions: We demonstrated using live imaging microscopy that pronephric tubular dilatation in three models of cystic kidney disease is secondary to an obstruction of the distal part of the pronephric duct. We propose a "come back" of the obstructive theory of cystic kidney diseases at least in zebrafish. growth. The mammalian target of rapamycin (mTOR), a key controller of cell growth and proliferation, is aberrantly activated in TECs of cystic kidneys. Continuous treatment with specific mTOR inhibitors retards rodent polycystic kidney disease. Here we examined the effect of pulse administration of the specific mTOR inhibitor everolimus on cystic kidney disease progression in the Han:SPRD rat, a model which resembles phenotypically human ADPKD. Methods: Four-week-old male heterozygous cystic (Cy/+) and wild-type normal (+/+) rats were administered everolimus or vehicle (3 mg/kg/day) once daily by gavage feeding for 12 weeks (continuous treatment). In a different schedule the drug was administrated for 5 weeks followed by 7 weeks without treatment (pulse treatment). BUN, creatinine and everolimus blood trough levels were monitored throughout. At week 16 the rats were sacrificed and kidney weights were measured to calculate the ratio of 2 kidneys/total body weight (2K/TBW). Cyst volume density was measured and the ratio of cyst volume to total cortex area was determined. Glomerular tuft areas were also measured and the glomerular volume (GV) was subsequently estimated. Results: A 5-week pulse everolimus treatment resulted in a long-lasting decrease in cystogenesis with preservation of kidney function (BUN, creatinine) (ARPKD) . Both PKHD1 and Pkhd1, its mouse ortholog, are associated with a complex splicing pattern that yields a high number of alternative transcripts. Gene-targeted mouse models suggest that Pkhd1 is functionally divergent in kidney and liver and that distinct transcripts are associated with specific roles. To identify and characterize key transcripts and their potential functions, we have examined the transcriptional profile of this gene in kidney and liver, in wild type (WT) and Pkhdl cl/cl mice. The cl spontaneous mutation occurs in exon 48, leading to a frameshift (c.7589delGGinsT). Homozygous mutants develop biliary dysgenesis and cystic liver disease by 1 month of age, but no morphological evidence of renal abnormalities. Methods: Long-and short-range RT-PCR were used to amplify transcripts from both mouse tissues, using a large set of primer pairs. Products representative of distinct transcripts are being subcloned and sequenced. Results: Experiments in WT kidneys and livers revealed different transcript profiles between the two organs. Comparative analysis of WTs and MUTs, in turn, showed specific isoform patterns for both kidney and liver in the MUTs. The systematic characterization of the products is allowing us to develop a catalog of organ-specific and disease-related transcripts. To date, we have analyzed more than 100 products amplified from kidney cDNAs with primers positioned in exons 1 and 67. Among the 24 transcripts fully-characterized thus far, 12 represent 6 transcripts expressed in both WT and MUT kidneys, while 5 were amplified only in WTs and 7 were specific to the MUTs. All 11 transcripts isolated from WTs appear to preserve the aminoacid sequence of the Pkhd1 longest open reading frame (ORF), 7 of them using the original translation start site (TSS). In contrast, 3 of the 7 MUT-specific transcripts likely do not preserve this ORF, and only 3 MUT-specific transcripts use the original TSS. Prediction scores for the acceptor and donor sites of all transcripts (with a single donor site exception) were >0.70. Analyses of liver WT and MUT transcripts, as well as products amplified with other strategic primer pairs, are in progress. Lastly, in situ hybridization experiments are in progress to confirm key observations at the tissue level. Conclusions: Taken together, our data demonstrate that Pkhd1 undergoes tissue-specific alternative splicing and suggest that the transcriptional processing is altered in the mutant gene. Moreover, the ORF analyses suggest that most of the WT alternative transcripts are likely functional, while several of the newly generated MUT transcripts may encode significantly shorter related proteins, or be non-functional. We conclude that the integrity of Pkhd1 is essential for transcriptional processing and dysfunctional splicing may be involved in ARPKD pathogenesis.
SO013
EVEROLIMUS PULSE TREATMENT HALTS
Introduction and Aims:
Hepatocyte nuclear factor-1 beta (HNF-1b), encoded by the TCF2 gene, is responsible for maturity-onset diabetes of the young type 5 and developmental nephropathies. Objectives: To describe clinical spectrum, natural history and genetic findings of diseases linked to TCF2 gene anomalies from foetal life to adulthood. Methods: Multicenter, descriptive study: 35 patients with TCF2 gene anomalies, 33 prenatally diagnosed including one in utero death, 2 postnatally diagnosed. Annual standardized clinical, radiological and biochemical evaluation. Results: Thirty three patients were prenatally diagnosed with developmental nephropathies: 18 foetuses had bilateral hyperechogenic kidneys, 10 had hyperechogenic kidneys with controlateral multicystic dysplastic kidney (MCDK), 2 had unilateral multicystic kidneys, one foetus had bilateral renal hypoplasia, one had renal agenesis with controlateral hypoplasia and one had non viable bilateral MCDK. Twenty one foetuses had cysts (63.6%). The mean prenatal renal length was 0.29±1.45 SD. After birth, renal growth was impaired conducting to small kidneys with a mean postnatal renal size of -0.93±1.66 SD. In patients with a solitary kidney there was no compensatory hypertrophy. At the last visit, 28 patients had cysts (82%), mainly cortical microcysts (23 patients). After a mean follow-up of 90.65±80.4 months, 33 patients demonstrated bilateral nephropathies and 1 patient had unilateral MCDK. The mean glomerular filtration rate (GFR) was 77.8±32.9 ml/min/1.73m 2 . Seventeen patients had a GFR ≥ 90 ml/min, six a GFR of 89 to 60 ml/min, seven a GFR of 59 to 30 ml/min, two a GFR of 29 to 15 ml/min and two patients had end stage renal failure. The mean annual decline of the filtration glomerular rate was 3.4 ml/min/year Extra renal manifestations included diabetes, hyperuricaemia, cholestasis, exocrine pancreatic insufficiency with low faecal elastase and asymptomatic pancreatic hypoplasia. The main TCF2 gene anomaly was a complete heterozygous deletion (20/35 patients). We found 10 different heterozygous point mutations: 4 missense mutations (p.G76C in 3 patients, p.Q253P in two patients of the same family, p.G285D, p.N289D), 3 splicing mutations (c.IVS1-1G>A, c.IVS1+6C>T, c.IVS6+ 1G>A), 1 nonsense mutation (p.Q454X), 1 frameshifting mutation (c.717delG), 1 involving the initiation codon (p.M1 or c.3G>A in two twins), and 1 single-exon deletion (deletion of exon 4). Sixty six percent of the genetic anomalies appeared de novo. Conclusions: TCF2 gene anomalies are associated with variable post-natal renal and non renal phenotypes. Therefore, close post-natal follow-up of patients with TCF2 gene anomalies is strongly recommended. Introduction and Aims: Midkine (MK) is a heparin-binding growth factor, and promotes chemotaxis of leukocytes in the animal models of an ischemic renal reperfusion injury (Sato W. et al., J Immunol 2001; 167: 3463-3469) and a diabetic nephropathy (Kosugi T et al., Am J Pathol 2006; 168; 9-19) . The enhanced expression of MK was detected in the proximal tubules after ischemic injuries. Here, we evaluated whether human MK is shed into urine from the tubular epithelial cells, and may serve as a potent urinary biomarker of acute kidney injuries in human. Methods: Cultured human tubular epithelial (HK2) cells were treated with hypoxia (1% O 2 +5%CO 2 ) or 20 μM BSA. Cell lysates and culture media were subjected for western blot analysis. For the measurement of urinary MK, 583 patients, including controls (n=33), patients with different forms of acute tubular necrosis (ATN) (n=33), and patients with other chronic renal diseases (n=517), were studied. Urinary MK level was determined by enzyme-linked immunoassay. Results: Western blot analysis showed that the increased expression of MK was detected in the culture media from HK2 cells treated with hypoxia, but not from HK2 cells treated with 20 μM BSA. There were no differences in the MK expression in the cell lysates. The urinary MK levels were significantly higher in patients with ATN ( 546.4±695.7, n=33) compared to levels in patients with other chronic renal diseases (26.9±80.2, n=516) or controls (2.1±11.0, n=33). For concentration in urine of MK, the receiver-operating characteristic (ROC) curve analysis for diagnosis of ATN showed that sensitivity was 97.0%, and specificity was 91.1% for a cut-off value of 70.0 pg/ml. Conclusions: A shedding of human MK was detected in the urine from the patients with ATN. Furthermore, urinary MK level may serve as a sensitive biomarker of ATN facilitating the early diagnosis of the disease. 
SO017 FACTORS AFFECTING POST-HEART SURGERY
Methods:
We have analysed the database in order to identify peri-operative predictors of severe kidney damage, expressed by two primary outcomes: Injury (creatinine doubling and/or renal replacement therapy -RRT-need) and Failure (need of RRT). A special focus was made on the role of the CBP time. A total of 11,681 records were analysed: 11,092 CBP procedures and 589 off-pump. Data processing included descriptive statistics (Student's T test and c 2 test), univariate and multivariate analyses. Results: The incidence of kidney injury was 7.2%, failure 2.7%. Both increased significantly the ICU as well as the hospital stay (p<0.0001, Mann-Whitney test). On-pump procedures were followed by Failure and RRT slightly, but significantly more often than off-pump ones (1.84 vs. 1.02%, p=0.007). Mortality was significantly greater in failure (43.1%) than injury (26.2%, p<0.05). Subdividing the CBP time in quintiles (<53 min, 54-71, 72-92, 93-122 and 123-591 min) the incidence of injury and death rate were similar up to the 4 th quintile and acutely increased only in the last quintile. Even with the univariate analysis, the odds ratio (OR) for injury risk was stable up to 122 min (1.76, 1.81, 1.84), while it was 3.84 for the 5 th CBP quintile (> 122 min). Most relevant risk factors, both pre-and post-surgery, were sepsis (OR 37), low cardiac output (19.7), intra-aortic balloon pump (16), shock (8.09), need for inotropes (6.99), ejection fraction <30% (5.6), pre-operative creatinine (3.87 per 1 mg increase), previous myocardial infarction (3.8). Finally, at the multivariate analyses, the CBP time quintiles, both for injury and failure, did not turn out to be significant, and the presence of sepsis (OR 5.49), low cardiac output states (5.3), pulmonary dysfunction (2.8) and pre-operative creatinine (2.3) remained the most relevant risk factors.
Conclusions:
To conclude, the responsibility of the CBP time in itself in kidney damage seems lower than expected on the basis of the literature data, at least for a large duration range (<122 min). On the contrary, in most cases the occurrence of kidney damage is the result of the peri-operative clinical complications or prior kidney dysfunction. (MCV) that represents a parameter to quantify the amount of Stxs-PMN: Group 1 (MCV ≥ 1.5) high Stxs level, 6 cases; Group 2 (MCV < 1.5) low Stxs level, 12 cases. The median time interval between the sampling of PMN and the diagnosis of HUS was similar for the two groups: 7 and 8 days, respectively. The two Groups were compared for platelet and neutrophils counts, hemoglobin and serum creatinine levels, need for dialysis and/or transfusions and neurological complications. No significant differences in the trends of platelet and neutrophil counts were observed in any of the Groups. Conversely, serum creatinine was normal in Group 1, whereas it was increased in Group 2 during the whole period of observation. Accordingly, the percentage of patients needing dialysis was lower in Group 1 (30%) and also the duration of the dialytic treatment was significantly shorter (3.5±2.1 days) in Group 1 than in the Group 2 (50% and 12.8±5.8, respectively). By contrast neurological complications were more frequent in Group 1 than in Group 2. Conclusions: Our data suggest that HUS children with high circulating Stxs-PMN levels show more frequently neurological complications whereas the severity of renal involvement is higher in low-toxin patients. Our conclusion is that a self-amplifying circle triggered by low doses of toxins leads to the production of pro-inflammatory mediators of renal damage, while neurological complications are more likely due to sudden brain endothelial injuries imposed by large amount of toxins. Introduction and Aims: High cut-off hemodialysis (HCO-HD) effectively removes large quantities of serum free light chains (FLC) in multiple myeloma patients with cast nephropathy. Whether this translates to sustained reductions in serum FLC concentrations and improved patient outcome is undetermined. This study assessed the combination of HCO-HD and chemotherapy as a therapeutic strategy to rapidly reduce serum FLC concentrations in patients with multiple myeloma, dialysis dependent renal failure and cast nephropathy. Methods: Standard chemotherapy regimens were initiated in all patients. HCO-HD was undertaken using two Gambro HCO 1100 dialysers in series, for 8 hours daily for the first 5 days. Then 8 hours on alternate days through to 21 days. Blood and dialysate flow rates were 250ml/min and 500ml/min, respectively. Dialysis independence and patient survival in 17 patients treated with HCO-HD were compared with a case matched historical control population treated with standard high flux dialysis (n=17). Results: HCO-HD resulted in sustained reductions in serum FLC concentrations in 12 of 17 patients (median 86% (range 50-93)). These 12 patients became independent of dialysis at a median of 27 days (range 13-50). Five patients had chemotherapy stopped because of early infective complications and did not achieve sustained reductions in serum FLCs. These patients did not recover renal function and had a significantly reduced survival (P<0.002). Only two of 18 (11%) control patients became independent of dialysis. Figure 1 -rates of independence of dialysis were significantly greater in study patients (solid line) than controls (broken line), P<0.001. In both groups, patients with cast nephropathy who recovered renal function (solid line) had a significantly improved survival compared with those who remained dialysis dependent (broken line), P<0.012 (figure 2). Conclusions: In conclusion, extended HCO-HD resulted in sustained reductions in serum FLC concentrations in patients with cast nephropathy. This was associated with an increased rate of renal recovery and improved survival. Absence of routine DM practices was associated with significantly increased mortality risk. Pts. from facilities without routine practices for foot exam or for HbA1c monitoring had significantly higher mortality risk when practices were modeled independently or with all three practices in one model (Table  1) . DM care provided by either an endocrinologist or nephrologist as compared to a PCP when modeled independently was associated with a significantly lower mortality risk (RR:0.6, p=0.015 and RR:0.7, p=0.046, respectively). Because multifaceted care is most effective for the management of DM, facility DMS was created by combining DM management practices. Progressively lower facility DMS was significantly associated with progressively increasing mortality risk. A score of 2 or below, characterized by less frequent DM POC, had a RR of 1.53 (p=0.02). These findings suggest the importance of fulfilling guideline recommendations since even a reduction in frequency of one of the practices can significantly increase the risk of mortality.
SO018
SHIGA TOXINS BOUND TO POLYMORPHONUCLEAR LEUKOCYTES (Stxs-PMN): CLINICAL OBSERVATIONS IN CHILDREN WITH HEMOLYTIC UREMIC SYNDROME (HUS)
Laura
SO019 FREE LIGHT CHAIN REMOVAL HEMODIALYSIS INCREASES RENAL RECOVERY RATE AND IMPROVES PATIENT SURVIVAL IN PATIENTS WITH CAST NEPHROPATHY
Diabetes 1 SO020 THE IMPACT OF DIABETES-SPECIFIC PROCESSES OF CARE (POC) ON CLINICAL OUTCOMES OF DIABETIC HEMODIALYSIS (HD) PATIENTS: THE DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY (DOPPS)
Conclusions: Our analyses demonstrate that 1) large variations exist in the delivery of DM POC to the diabetic ESRD population, 2) facilities with DM management practices tend to have lower mortality rates compared to those that do not, and 3) the DMS developed from these findings requires validation in other HD settings. Disclosure: The DOPPS is supported by research grants from Amgen, Inc. and Kirin Pharma Co., Ltd., without restrictions on publications.
Introduction and Aims:
In humans, diabetes is a major risk factor for chronic kidney disease (CKD). Anaemia is a common complication of CKD; it reduces quality of life and can exacerbate macrovascular and microvascular complications of diabetes. Erythropoiesis-stimulating agents (ESAs) have been shown to be effective in correcting anaemia, but can also have pleiotropic effects that could produce additional benefits in diabetes.
We examined the effects of epoetin delta (Dynepo ® , Shire plc), a humancell-derived ESA, on measures of nerve blood flow, nerve function and erythropoiesis in diabetic rats. Methods: Studies used Sprague-Dawley rats. Streptozotocin-induced diabetes was left untreated for 4 weeks, followed by 4 weeks of epoetin delta treatment. Study 1 was dose-ranging and measured motor nerve conduction velocity (NCV). Rats were treated with epoetin delta 21-1667 IU/kg, once weekly (QW) or thrice weekly (TIW). In study 2, epoetin delta doses of 150 IU/kg (QW or TIW) or 1500 IU/kg (QW) were used for in-depth analysis of nerve perfusion and function. In unanaesthetized rats, tactile allodynia (tested by foot withdrawal reflexes to von Frey hair stimulation) and thermal hyperalgesia (tested by noxious heat stimulation) were studied. Under thiobutabarbital anaesthesia, sciatic nerve nutritive endoneurial blood flow was assessed by hydrogen-sensitive microelectrode polarography, followed by measurement of motor NCV in the sciatic nerve and sensory NCV in the saphenous nerve. Blood samples were analysed for haematopoietic effects. Results: In study 1, diabetes reduced motor NCV by 21%; this was corrected by epoetin delta treatment. ED 50 values were similar for QW and TIW administration (mean ± SEM: 94.7±1.2 IU/kg and 54.1±1.3 IU/kg, respectively). In study 2, a 53.7±4.2% reduction in sciatic nerve blood flow was corrected by epoetin delta (49.2±10.1% [150 IU/kg, TIW]; 50.0±7.0% [150 IU/kg, QW]; and 74.3±4.6% [1500 IU/kg, QW]). Diabetic rats showed tactile allodynia (threshold for foot withdrawal on stimulation reduced by 58%) and thermal hyperalgesia (foot withdrawal latency decreased by 24%). Allodynia was partially corrected (69%) by epoetin delta 150 IU/kg (QW or TIW) and completely corrected by 1500 IU/kg (QW). Similarly, thermal hyperalgesia was partially (64%; 150 IU/kg, QW or TIW) or completely (1500 IU/kg, QW) corrected. A 16% sensory NCV deficit was largely (84%) corrected by all doses. In both studies, haematocrit (Hct), haemoglobin (Hb), and red cell and reticulocyte counts were unaffected by diabetes or QW treatment. For TIW treatment, Hct, Hb and red cell count were elevated at the highest dose (1667 IU/kg) and reticulocyte count was increased at doses ≥ 186 IU/kg. Conclusions: We have shown that epoetin delta has a marked positive effect on nerve blood flow in diabetic rats, which was reflected by improved neural function. This occurred even at epoetin delta doses that did not promote haematopoiesis, representing a pleiotropic vascular effect of epoetin delta treatment that could be beneficial for the vascular complications of diabetes. Disclosure: This study was supported by a research grant from Shire plc. (102±74 vs 142±79, p=0.04 ). In patients with Ma-A the number of EPC was even more decreased (55±32 vs 142±79; p<0.001). Patients with Mi-A or Ma-A were also significantly different for the number of EPC (102±74 vs 55±32, p=0.01). By contrast, circulating progenitor cells, which have an important role in the haematopoietic system, were not significantly different among the 3 groups of type 2 diabetic patients with No-A, Mi-A or Ma-A (p=0.37).
SO022
DECREASED ENDOTHELIAL PROGENITOR CELLS IN
Conclusions:
In conclusion, this is the first study demonstrating decreased numbers of endothelial progenitor cells in type 2 diabetic patients with microalbuminuria or macroalbuminuria. Since low EPC are important predictors of future cardiovascular morbidity and mortality in nondiabetic high risk patients, these new findings could be relevant for the understanding of the high cardiovascular risk of type 2 diabetic patients with microalbuminuria or macroalbuminuria.
Introduction and Aims: Diabetic nephropathy (T1DN) and the associated renal failure account for the reduced life expectancy of patients with type 1 diabetes (T1DM). Although almost all patients with T1DM are affected by diabetic retinopathy over time, only 25 to 35% of these patients develop DN. Chronic hyperglycemia cannot fully account for the pathogenesis of renal complications. Genetic factors play an important role, as shown by familial studies. Angiotensin-converting enzyme (ACE) and the adducin (ADD1, ADD2, and ADD3) gene polymorphisms are associated with cardiovascular and DN risk factors, respectively. In a retrospective population study and in cell models, we investigated the combined effects of these polymorphisms. Methods: We randomly recruited 251 T1DM without DN and 141 T1DN with a mean follow-up of 5 years. All patients were genotyped for ADD1, ADD2, ADD3, and ACE polymorphisms. To clarify our epidemiological observations among the genotype studied, we investigated the combined effects of ADD2 and ACE on the membrane-bound ACE activity in fibroblasts. Results: Hardy-Weinberg equilibrium was respected for all polymorphisms studied. No significant differences were present in genotypes frequency between DN and control patients. T1DN carrying ADD2 T/ACE DD reached dialysis 50 months before than those carrying ADD2 T/ACE II-ID (ADD2*ACE Interaction p =0.009 after correction for confounders). Furthermore, in fibroblasts carrying the ADD2 T/ACE II+ID the membranebound ACE activity increased in T1DN (6.22±1.1 nanomoles of generated hippuric acid per milligram of protein per minute) than in control (3.74±0.7; p=0.09) Conclusions: The ADD2 permissive effect on ACE polymorphisms may have a determinant role in the progression toward end stage renal disease in T1DN. Moreover, these effects observed at cellular level may account for different renal protective effect of some gene modifier.
Introduction and Aims:
Epithelial cells of the thick ascending limb of Henles loop (TALH) involve different mechanisms and pathways in their osmotic adaptation and stability. The alteration in the expression of ER stress proteins is a part of the TALH-cells reaction to osmotic stress (Dihazi et al. 2005 (Dihazi et al. , 2006 . Methods: In order to map the expression changes of ER stress proteins under high osmotic stress and to understand the role of this protein in osmotic stress resistance and in the establishment of calcium homeostasis, in gel electrophoresis approach with fluorescence labeled cysteines combined with mass spectrometry analysis were performed with established TALH model cell lines. Results: The expression of ER stress proteins especially GRP78, GRP94, calreticulin, and Erp72, was significantly downregulated under osmotic stress (p < 0.05). GRP78 and calreticulin are actively engaged in regulation of free calcium concentration in the ER and the cytosol. Calcium imaging of NaCl stressed TALH-cells revealed time dependent elevation of Ca 2+ ions concentrations in the cytosol arising from release out of endoplasmic reticulum stores. In parallel RT-PCR and Western blot analysis showed a progressive decrease in calreticulin and GRP78 expression. Thapsigargin treated TALH-cells exhibit no calreticulin or GRP78 downregulation under hypertonic stress when compared to control cells. Conclusions: With our investigation we shed light on the important role of the down regulation of ER proteins in establishment of calcium homeostasis by TALH-cells under hypersomotic stress.
SO025
INHIBITION OF mTOR ARREST HIGH GLUCOSE-INDUCING GLOMERULAR MESANGIAL CELLS SENESCENCE BY UPREGULATION OF SIRT1
Guangyan Cai, Sifang Zhang, Xiangmei Chen, Bo Fu, Weiping Liu.
Department of Nephrology, Kidney Center and Key Lab of the People's Liberation Army, General Hospital of People's Liberation Army, Beijing, China
Introduction and Aims: The activation of mTOR plays a central role in diabetic nephropathy, but whether it is involved in senescence induced by high glucose in GMC still remain to be explored.SIRT1, an NAD-dependent deacetylase, is a principal modulator of pathways downstream of calorie restriction that produce beneficial effects on glucose homeostasis and insulin sensitivity. Methods: In this study, the senescence of primary GMC was induced successfully by high glucose (30 mM), meanwhile, High glucose increased the expression of mTOR mRNA and protein as well as downregulated the level of SIRT1 protein. RNA interference and nicotinamide, a known inhibitor of SIRT1, were used to inhibit the expression of SIRT1gene and decrease the activation of SIRT1 that determine the contribution of SIRT1 to GMC senescence.
Results:
The results showed RNA interference and nicotinamide can promote rat GMC senescence. NAD,which can activate SIRT1 by increasing the NAD/NADH ratio, while resveratrol, a polyphenolic SIRT1 activator, arrested senescence triggered by high glucose in rat GMC. Moreover, the mTOR pharmacological inhibitor rapamycin prevented senescence induced by high glucose in GMC by increaseing SIRT1protein expression and activity. Conclusions: These results demonstrated for the first time that inhibition of mTOR can arrest the senescence of GMC induced high glucose, and its mechanism is increasement of SIRT1protein expression and activity. (Kidney Int 69:1016 -1023 , 2006 ). The present study investigated whether apocynin (an inhibitor of NADPH oxidase) interferes with the action of the intrarenal renin-angiotensin system (RAS), subsequently attenuating RPTC apoptosis and tubulointerstitial fibrosis, independent of systemic hypertension. Methods: Adult male Agt-Tg mice were randomly divided into 4 groups: vehicle-treated Tg mice and Tg mice treated with apocynin, hydralazine (a vasodilator) or perindopril (an angiotensin-converting enzyme inhibitor). Non-Tg littermates served as controls. Systolic blood pressure (SBP) and albuminuria were monitored weekly until the animals were 20 weeks of age. Animals were then euthanized and their kidneys were processed immediately for assay of reactive oxygen species (ROS) [lucigenin assay], histology, and studies of apoptosis [terminal transferase-deoxyuridine triphosphate nick end-labeling or active caspase-3 and Bax immunostaining]. The mRNA and protein expression of pro-apoptotic genes [Bax and active caspase-3] and pro-fibrotic genes [transforming growth factor-beta 1 (TGF-β1), plasminogen activated inhibitor-1 (PAI-1) and collagen type IV] were quantified by real-time quantitative polymerase chain reaction assays and Western blotting, respectively. Results: Agt-Tg mice displayed significantly elevated ROS production, hypertension (SBP: 117 vs 98 mm Hg, p<0.001), albuminuria (0.8 vs 0.3 μg albumin/mg creatinine, p<0.01), tubular apoptosis, and interstitial fibrosis as well as augmented Bax, active caspase-3, TGF-β1, PAI-1, and collagen type IV gene expression as compared to controls. Apocynin and perindopril markedly attenuated these changes, but apocynin had no effect on SBP. Hydralazine treatment prevented hypertension and tubulointerstitial fibrosis but not RPTC apoptosis. In vitro, apocynin and perindopril but not hydralazine prevented the increase of ROS generation, cellular apoptosis and pro-apoptotic gene expression in rat immortalized RPTCs overexperssing the Agt.
Conclusions: These data demonstrate that intrarenal RAS action on RPTC apoptosis and tubulointerstitial fibrosis is mediated, at least in part, via ROS generation and TGF-β1 signaling, independent of systemic hypertension (supported by the Kidney Foundation of Canada and the Canadian Institutes of Health Research).
Introduction and Aims:
The precise source of interstitial fibroblasts present in the fibrotic kidney is unclear but evidence suggests epithelial to mesenchymal transition (EMT) as a significant source. Recent evidence has demonstrated that the Rho family of monomeric GTPases are key modulators of EMT, but the individual roles of the Rho isoforms A, B, and C had not previously been investigated. In this study we focus on the adherens junction component E-cadherin, and the mesenchymal marker α-smooth muscle actin (α-SMA).
Methods:
As an in vitro model of EMT we treated human kidney (epithelial) cells (HKC8) with 10ng/ml transforming growth factor β 1 and 10ng/ml epidermal growth factor for 5 days. 100nM short-interfering RNA (siRNA) was used to selectively silence RhoA, RhoB or RhoC. Two separate siRNA sequences were used to target each of the Rho isoforms in isolation and in combination. The efficiency and specificity of knock-down was ascertained by semi-quantitative PCR, quantitative PCR and immunoblotting. The expression of E-cadherin and α-SMA was determined by immunoblotting and semi-quantitative PCR. Rho-kinase 1/2 activity was blocked with 10μM Y27632. To study E-cadherin degradation 25μM proteasome inhibitor 1 (PI1) was utilised. Results: siRNA-mediated knock-down of Rho mRNA, of at least 65%, was maintained for 5 days. Knockdown of mRNA for one isoform did not affect the expression of the others, and reduction of mRNA corresponded to reduction of protein abundance by 48 hours after transfection. EMT-induced upregulation of α-SMA protein was blocked by RhoA abrogation, but not RhoB or RhoC. This effect of RhoA is independent of Rho-kinase 1/2 activity, as Y27632 co-treatment did not rescue α-SMA expression. In our EMT model E-cadherin expression was abolished by 5 days. However, inhibiting RhoA or RhoC expression accelerated E-cadherin protein loss, which was complete by 48 hours. RhoA knock-down resulted in the loss of E-cadherin mRNA whereas knockdown of RhoC did not. Using PI1, the loss of E-cadherin caused by RhoC knock-down was rescued. PI1 did not, however, rescue E-cadherin loss induced by silencing RhoA.
Conclusions:
The control of α-SMA gene transcription is specific to RhoA in our model, and is independent of Rho-kinase 1/2. Although the α-SMA promoter has previously been shown to be activated by TGFβ1 in a Rhodependent, but Rho-kinase 1/2 independent, manner, this phenomenon was not known to be RhoA specific. Pivotal to EMT is the loss of adherens junctions. Whilst Rho activity is known to be required for the maintenance of these junctions it has also been demonstrated that over-activity of Rho can lead to junction disassembly. Interestingly, we show that loss of RhoA appears to prevent expression of E-cadherin at the mRNA level whilst loss of RhoC does not. Conversely, inhibition of RhoC expression, but not that of RhoA, leads to increased degradation of E-cadherin. These results suggest that RhoA and RhoC are required to be expressed at a basal level to maintain E-cadherin at the adherens junction, but each does so by a different mechanism. Introduction and Aims: Chronic kidney disease (CKD) is associated with a dramatic increased risk of cardiovascular morbidity and mortality. In the general population, carotid intima media thickness (IMT) assessed using ultrasonography is an accepted marker of atherosclerotic plaque burden. However, as advanced CKD is also a state of marked fluid overload and endothelial dysfunction, we assessed the impact of these factors on IMT before and after renal transplantation. Methods: We studied 406 patients with different stages of non-diabetic CKD (50% males, 46±12 years) and 58 kidney transplant recipients (57% males, 27±6 years), testing the relationship between IMT, assessed by ultrasonography, and selected biomarkers. We also investigated 80 healthy volunteers matched to the CKD group (50% males, 46±11 years) as well as 63 healthy volunteers matched for the transplant receipients group (48% males, 27±6 years), and these controls underwent similar testing. Results: Patients had significantly elevated IMT compared to matched controls, and IMT correlated with eGFR. Following transplantation, IMT levels decreased concurrently with weight, and within 90 days posttransplantation had reached levels comparable to those of the controls, ie. 0.6 (range 0.4-0.7) mm. In multivariate analysis, eGFR (p<0.001), SBP (p<0.001), iPTH (p<0.001), HOMA (p<0.05) and DBP (p<0.05) were all found to be independently related to IMT levels in CKD patients. Similarly, only change in body weight (p<0.05) and in serum uric acid level (p=0.001) were independently related to the change of IMT level following transplantation. Conclusions: While CKD was associated with a markedly increased IMT, following renal transplantation IMT was normalized within 90 days. This normalization was independently associated with a reduction of body weight (taken to represent normalization of fluid balance) and a decrease in serum uric acid levels. Our data thus suggests that in CKD patients, IMT is more closely associated with fluid status than with atherosclerosis. . Lumen area and length was traced in Olympus DP-Soft 5.0. Mean AA diameter was calculated using the formula (mean diameter) = (lumen area)/(lumen length).
ERA-EDTA Fellows
SO028 RAPID NORMALIZATION OF CAROTID INTIMA-MEDIA THICKNESS FOLLOWING RENAL TRANSPLANTATION IN NON-ATHEROSLCEROTIC PATIENTS WITH CHRONIC KIDNEY DISEASE CORRELATES WITH NORMALIZED SERUM URIC ACID LEVELS
SO029 ABNORMAL CONTRACTILE ENDURANCE AND KINETICS TO ANG II IN RENAL RESISTANCE VESSELS OF NOTCH3 KNOCK OUT MICE
Results: AA diameter was similar in WT (24.3±2.1 μm) and Notch3-/-(24.2±1.6 μm). Vessel wall thickness, however, was reduced in Notch3-/-(14.5±1.0 μm) compared to WT (19.9±1.7 μm, p < 0.01). Further analysis revealed that cell wall diameter measured at opposite positions in randomly chosen cross-sections of the vessels varied more in Notch3-/-( 9.7±1.5 μm) than in WT ( 2.9±0.4 μm, p < 0.001), indicating an asymmetric vessel wall structure of the Notch3-/-AA. During the initial 5 s after ANG II stimulation (10 -7 M), AAs from Notch3-/-animals displayed an exaggerated lumen diameter response (67±5% of baseline) compared to WT (86±5% of baseline, p < 0.05). In contrast, the sustained contractile response measured at 180 s was much smaller in KO compared to WT (83±5% of baseline vs. 61±6% of baseline, respectively, p < 0.05). Similar differences were found at 10 -8 M ANG II. To test dependence of extracellular Ca 2+ , the lumen diameter response was studied in calcium free medium (EGTA 10 -4 M). The exaggerated initial response to ANG II 10 -7 M in Notch3-/-vessels was maintained, demonstrating importance of intracellular Ca 2+ release. Furthermore, the sustained contractile response was unaltered in KO vessels after Ca 2+ removal (83±5% of baseline vs. 89±8% of baseline with and without Ca 2+ , respectively, at 180 s), whilst WT contractility was reduced (61±6% of baseline vs. 85±8% of baseline with and without Ca 2+ , respectively, at 180 s, p<0.05).
Conclusions:
The present data suggests that renal resistance vessels of Notch3-/-display an abnormal defective response to vasoconstrictors. This defect is probably due to a structural deficiency; a thinner and asymmetrically organized vessel wall. As a likely consequence, compensatory Ca 2+ i mobilization from intracellular stores may occur during the initial phase of contraction after ANG II stimulation, resulting in an exaggerated early response that AAs of the Notch3-/-are unable to sustain. This result indicates that a functional Notch3 gene plays an important role in the control of renal vascular resistance. Introduction and Aims: CD36 is an 88kDa glycoprotein which is present on the cell surface of many different cell types including monocytes/macrophages, endothelial cells, and myocytes. CD36 has numerous functions such as being a scavenger receptor, long chain fatty acid transporter, and receptor for thrombospondin-1. In CD36-deficient patients, increased susceptibility to type 2 diabetes has previously been documented, while CD36-KO mice have been shown to have retarded atherosclerosis progression. The aim of the study was to evaluate the association between a common CD36 polymorphism (CD36 27645 ins/del) and comorbidities as well as survival in end-stage renal disease (ESRD) patients. Methods: CD36 27645 ins/del polymorphism was evaluated in 310 stage 5 CKD patients, close to start of renal replacement therapy, by size separation through gel electrophoresis. For polymorphism frequency comparison, an additional cohort of 562 healthy controls was studied. Fasting blood samples were analyzed at baseline for routine biochemistry and hematology, markers of inflammation and oxidative stress and cardiac injury (troponin T). The patients were followed prospectively, and the three-year all cause and cardiovascular mortality was analysed. Results: The distribution of the CD36 27645 ins/del polymorphism was similar in ESRD patients and in the control group. The CD36 27645 del variant was associated with lower concentration of hemoglobin, and higher levels of troponin T and 8-OHdG in an allele-dependent manner, as well as with higher prevalence of diabetes mellitus. Furthermore, the CD36 27645 del variant was an independent predictor of three-year cardiovascular mortality in ESRD patients (HR 2.56; p<0.002 Introduction and Aims: Polycystin-2 (PC-2), a protein involved in autosomal dominant polycystic kidney disease (ADPKD) encoded by PKD2, is a non-selective cation channel, recently implicated in the function of the primary cilia. PC-2 has a control on the intra-cellular calcium level. The basal body is a modified centrosome. The function of PKD2 in the centrosome biology is unknow. An abnormal centrosome number is frequently observed in cancer cells and linked to genomic instability. Our aim is to study the impact of modulation of PC-2 in vivo on the centrosome control number. Methods: We used two transgenic mice lineage. One overexpressed the human polycystin 2, the second is a knock out mouse for Pkd2. We extract fibroblasts from transgenic mice and wild type mouse at various ages. We also knock down Pkd2 expression in wild type fibroblast using siRNA. Genomic stability was studied by FISH. The centrosome number was counted after labelling with an antibody against γtubulin. The activity of the calcium/calmodulin-dependent protein kinase II (CaMKII) was inhibited with the KN-93 inhibitor. Results: We observed that fibroblasts from a transgenic mouse line overexpressing human PKD2, present with mitotic instability. The karyotype analysis schowed abnormal number of chromoses. This mitotic instability is linked to the formation of supernumerary centrosome (30% of fibroblasts had more than 2 centrosomes). Knocking down Pkd2 expression in normal mouse fibroblasts by siRNA results in an abnormal over-duplication of centrosomes. We also observed centrosome overduplication in mouse embryonic fibroblasts derived from homozygous mutant Pkd2
SO030 CD36 27645 ins/del POLYMORPHISM IS ASSOCIATED WITH CARDIOVASCULAR MORTALITY IN END-STAGE RENAL DISEASE PATIENTS
LacZ/LacZ KO embryos. In the fibroblast derived from heterozygotes, the abnormal centrosome number is intermediate betwen KO and wild type. This phenotype is corrected by incubation of transgenic or KO cells with an inhibitor of calcium/calmodulin-dependent protein kinase II (CaMKII), indicating an implication of this pathway in centrosome overduplication induced by perturbation of PC-2 expression. The wild type fibroblast, as previously described, exhibited an abnormal centrosome number after incubation with KN-93. We propose that PC-2 abnormal expression protects normal cells from centrosome overduplication after CamKII inhibition. In addition in the fibroblasts with an excessive number of centrosome we observed no primary cilia or more than one primary cilia. Conclusions: Pc-2 plays a role in the control of cell division through the control of centrosome duplication. The anomalies in the number of centrosome is linked to genomic instability in cancer via the perturbation of mitosis. We propose a model where perturbation of PKD2 expression generates excessive centrosome duplications. The abnormal number of centrosome could be responsive for the defective mitotic axis observed in tubules of polycystic mice. In addition we observed that the overduplication of centrosome secondary of CamKII inhibition could be inhibited by non regulated PC-2 expression. This could be a new way to control centrosome number in cancerous cells.
Introduction and Aims:
Calcineurin inhibitors like FK506 (Tacrolimus) are routinely used for immunosuppression following transplantation in conjunction with an antiproliferative agent. The use of these drugs is limited by many side effects such as reduction of the glomerular filtration rate and renal tubular acidosis (RTA), mainly of the distal type. Therefore, we investigated the effect of FK506 on rat kidney function and expression of key acid-base transporters to elucidate the underlying molecular mechanisms/changes. Methods: We used a rat model injecting the animals subcutaneously with 1mg/kg body weight FK 506 for 11 or 16 days. Control animals were injected with 0.9% NaCl solution for the same time period. In addition, metabolic acidosis was induced by adding 0.28M NH 4 Cl to drinking water for 2 or 7 days. Results: Under normal conditions systemic acid base status was similar in both groups. However, after 2 and 7 days acid loading with 0.28M NH 4 Cl, the Tacrolimus treated animals showed a more severe metabolic acidosis, elevated blood glucose levels, and reduced GFR. Excretion of phosphate was lower in the Tacrolimus treated animals with an acid load. Despite the more pronounced acidosis in the Tacrolimus group after 2 days acid loading, urine pH was more alkaline indicating distal RTA. Interestingly, ammonium excretion was significantly higher in these animals. After 7 days acid load all differences related to acid-base handling were equalized in both groups. Western blot analysis revealed reduced expression of the a4 and B1 subunits of the vacuolar H + -ATPase under normal conditions but a higher abundance of a4 after induction of metabolic acidosis in cortex and medulla. The expression of the acid-secretory type A intercalated cell specific Cl -/HCO3 -exchanger AE1 in total kidney was lower under normal conditions and significantly increased after induction of metabolic acidosis for 2 days. The abundance of the type IIa and IIc Na + /phosphate cotransporter as well as the B2 subunit of the vacuolar H + -ATPase were reduced under normal conditions in the Tacrolimus treated animals and significantly increased after acid loading. Conclusions: In summary, treatment with Tacrolimus did not induce renal tubular acidosis in rats under baseline conditions. Further, Tacrolimus treated rats developed a more severe hyperchloremic metabolic acidosis under an acute oral acid load after 2 days, but this effect was equalized after 7days, indicating an acute and transitory impairment of the renal adaptation to acidosis. Key transport proteins involved in renal acid base handling as vacuolar H + -ATPase, the Cl -/HCO3 -exchanger pendrin or the acid-secretory type A intercalated cell specific Cl -/HCO3 -exchanger AE1 were downregulated in animals treated with Tacrolimus. However, induction of metabolic acidosis contributed to an appropriate upregulation of these transporters under acid challenge. In conclusion, treatment with Tacrolimus induced transient renal tubular acidosis after an oral acid challenge of 2 days in rat. Thus, Tacrolimus may have a decelerating effect on the renal adaptation to an acute acid challenge.
SO033 GLUCOSE DEGRADATION PRODUCTS MAY IMPAIR THE HEAT SHOCK RESPONSE
Thorsten Onno Bender 1 , Janusz Witowski 2 , Achim JörresIntroduction and Aims: Cellular damage is balanced between toxicity induced injury and counteracting cellular responses. We have previously shown that exposure of mesothelial cells to peritoneal dialysis fluids (PDF) not only caused toxic injury but also induced cytoprotective heat shock proteins (HSP). Recently glucose degradation products (GDPs) were identified as probably the most important biocompatible impairing component of PDF. But up to now the role of GDPs on HSP expression is not known. This study was performed in order to evaluate the impact of GDPs on the heat shock response. Methods: Mesothelial Cells (Met5a) where incubated in the presence of increasing doses of eight glucose degradation products found in PDF (Acetaldehyde, Formaldehyde, Glyoxal, Methylglyoxal, Furaldehyde, . After 24 hours of exposure, viability was assessed by LDH release (as marker for toxic injury) and protein was harvested for HSP-72 determination by Western blotting (as marker for cytoprotective cellular response). All data presented as % of control ± SEM. Formaldehyde (n=7), Glyoxal (n=3), Methylglyoxal (n=5) for LDH release and Formaldehyde (n=1), Glyoxal (n=3), Methylglyoxal (n=5) for HSP-72.
Results: From the eight GDPs tested three (Formaldehyde, Glyoxal and Methylglyoxal) resulted in a dose dependent increase of LDH release (1st figure) . Interestingly, these increases were associated with absence of adequate HSP induction (2nd figure) . This is in contrast to results obtained from past studies regarding other biocompatibility impairing components of PDF like acidic pH or lactate which resulted in significant HSP induction before cellular viability was impaired. The other GDPs did not result in significant LDH release or HSP-72 expression.
Introduction and Aims:
Severe chronic kidney disease (CKD) is associated with mineral disorders which can result in pathological bone structure, and increased risk of falling from associated comorbidity and therapy. Clinical significance is unclear especially in older people who have also increased prevalence of osteoporosis with incident hip fractures. The aim of this study was to examine whether CKD at older ages is associated with hip fracture related mortality. Methods: Cohort study of people aged 75 and over participating in a cluster randomised trial of health and social assessment of older people in the community between 1994-8 in the UK. There were 13177 (87%) participants in 53 general practices who had a serum creatinine measured in local laboratories at baseline. Estimated glomerular filtration rate (eGFR) was derived from the Modification of Diet in Renal Disease formula (MDRD). Analyses are based on deaths up to end November 2005 for any reported fracturing of the hip based on ICD codes on the death certificate sent to the Office for National Statistics. Participants were also followed up in detail over a two year period after inclusion into the trial to produce a record of all hospital admissions and corresponding causes. We used propensity scores to appropriately adjust for all potential confounders (relating to both falls risk and bone structure) in the Cox regression models.
Results: There were 124 hospital admissions for hip fractures in the first two year, and 84 hip fracture related deaths over 84117 person years of follow-up. In analyses with outcome hip fracture related deaths compared to an eGFR>60 ml/min/1.73m 2 , the age and sex-adjusted hazard ratios for eGFR 45-59 and <45 ml/min/1.73m 2 were 1.06 (95% confidence interval: 0.71, 1.58), and 1.97 (1.12,3.50), respectively. When adjusting for all confounders using propensity scores, the adjusted hazard ratio for participants with eGFR<45 ml/min/1.73m 2 compared to those with eGFR above was 1.81 (1.11, 2.94). There was no evidence for an association between eGFR and hospital admissions for hip fracture in the first two years after trial inclusion. Conclusions: Amongst older people, an eGFR of <45ml/min/1.73m 2 is independently associated with a two fold increase in hip fracture related mortality. Larger studies with longer follow up are needed to examine the association of CKD with incident hip fractures, and thereby separate potential effects of CKD on fracture risk and case fatality.
Microalbuminuria (MA) is a strong independent predictor of CVD events and all-cause mortality. Sparse data are currently available, however, on how potentially modifiable risk factors such as diet may influence albuminuria. Methods: We identified 3121 women participating in the Nurses' Health Study, an established longitudinal cohort study, who had diet data and urinary albumin-to-creatinine ratios (ACR) measured on urine collected in the year 2000. This group included 674 women who comprised a substudy of type 2 diabetics. Cumulative averaged diet quality scores and diet patterns (prudent vs. Western) over 14 years were derived from validated semi-quantitative food frequency questionnaires from 1984, 1986, 1990, 1994, and 1998 . Higher diet quality scores generally reflect greater intake of vegetables, fruits, and whole grains and lower intake of red and processed meats and saturated fats. Multivariable (MV) logistic regression was used to assess for associations between quartiles of energy-adjusted diet quality indices, including the Healthy Eating Index (HEI), Revised Healthy Eating Index (RHEI), Diet Quality Index Revised (DQIR), Recommended Food Score (RFS), and Mediterranean Diet Index (MED), and presence of MA or greater (defined as ACR >= 25 mcg/mg). Results: Mean age was 66±6.7 years, 89% Caucasian, 54% with HTN, 23% with diabetes, 5% with CVD, 6% current smokers, mean BMI 27.1±5.8 kg/m 2 , and mean eGFR 77±18 ml/min/1.73 m 2 by 4-variable MDRD equation at time of ACR measurement. In this group, 177 (5.6%) women had MA or greater. MV models revealed that higher quartiles of diet quality scores were consistently associated with decreased odds ratio of presence of MA or greater with the exception of RFS (Table 1) . Furthermore, the highest quartile of Western diet pattern score was significantly and directly associated with an OR 2.22 (95% CI 1.20 to 4.10, p-for-trend=0.007) for MA or greater. 
Conclusions:
Higher diet quality is inversely associated with presence of MA whereas the Western diet pattern high in red meat, refined grains, sweets, and high-fat dairy products is directly associated with presence of MA. Therefore diets higher in fruits, vegetables, whole grains, and fish may protect against development of MA and deserve further study. Introduction and Aims: Serum phosphate has been related to significant morbidity and mortality in the dialysis population. Less is known about the relationship between serum phosphate levels and mortality in patients with chronic kidney disease (CKD) not on dialysis although one study has shown an association between hyperphosphataemia and mortality in a veteran cohort with raised creatinine measurements. We investigated the prognostic associations of baseline serum phosphate in the chronic renal insufficiency standards implementation study (CRISIS) which is a prospective epidemiological study of patients with CKD stages 3-5 not on dialysis. Methods: 934 patients were available for study and their mean follow up period was 1260 days (± 539). Serum phosphate was divided into quartiles in order to evaluate associated significant factors. Linear regression was also performed and adjusted for eGFR, PTH, proteinuria, diabetes, cardiovascular disease and age. Results: The mean age of the patients was 64.5 (± 14.2) years, estimated glomerular filtration rate (eGFR) 31.1ml/min (± 14.5), 34% female, serum phosphate 1.2mmol/l (±0.3), corrected calcium 2.3mmol/l (±0.2), parathyroid hormone 90.2pg/ml (±96.3), proteinuria 1.1g/d (±1.8) and 30.4% had cardiovascular disease. Increasing phosphate was positively associated with mortality (p<0.005) with an absolute risk reduction of 14.3% and a relative risk reduction of 21.2% demonstrable between the lowest (phosphate <1mmol/l) and highest (phosphate >1.35mmol/l) quartiles. In total there were 244 (26%) deaths during the period of follow up. Serum phosphate was also positively associated with parathyroid hormone, proteinuria, diabetes, smoking and female sex. It was negatively associated with haemoglobin, diastolic blood pressure and weight. No relationship was found with baseline eGFR. On multivariate linear regression a significant association was maintained with mortality, parathyroid hormone, proteinuria, haemoglobin, gender, diabetes, weight and smoking.
SO036
PROGNOSTIC ASSOCIATION OF SERUM PHOSPHATE IN PATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS
Helen
Conclusions: This prospective study shows that serum phosphate is independently associated with all-cause mortality in chronic kidney disease stages 3-5 (not on dialysis). This effect holds true even with serum phosphate values within the accepted normal range -eg 87% of patients had a serum phosphate less than 1.5mmol/l (KDOQI upper limit in CKD). Clearly phosphate control is of major importance in CKD; further studies are merited in order to investigate whether lower targets for phosphate control are indicated in CKD patients. Disclosure: Funded by an educational grant from Genzyme. (AJCN 85, 2007) . In previous studies it was shown that the device can be used to assess FO (EDTA 2007) and malnutrition. The aim of this study was to show if protein malnutrition or fluid overload is the major predictor of mortality in HD patients. Methods: LTI and FO were determined via the BCM in 156 patients. To evaluate LTI and fluid overload, reference ranges were set up on basis of a reference population (RP) of n=1000 normal subjects between 18-85 years. To analyse protein malnutrition patients were separated into LTI groups (low if LTI < 10th percentile of the RP, normal if LTI was > 10 th percentile of the RP). Patients were regarded as fluid overloaded, when FO was > 2L at the start of the HD-treatment. Survival analysis was performed using the Gehan-Breslow method, adjusting for age, sex and diabetes. The relative risks were calculated on the basis of the odds ratios. Results: Mean time on HD before measurement was 3.5±5.7 years, mean age was 67±13 yrs. After 2 yrs, 18% of all patients had died. The low LTI group showed a significantly greater mortality (p=0.009) compared to the normal LTI group. Also the high FO group showed a significantly increased mortality (p=0.005). After 2 yrs, 27% of patients in the low LTI group had died, while only 12% had died in the normal group. The subgroup of patients with LTI<10% and FO>2L had a 2,4 fold increased risk of dying compared to the subgroup with normal LTI and normal FO. Cardiology, Turku University Central Hospital, Turku, Finland Introduction and Aims: Among patients with end-stage renal disease (ESRD) the risk of cardiovascular disease is 10 to 20 times higher than in general population. Even minor renal dysfunction is a powerful cardiovascular risk factor. Numerous heterogeneous cardiovascular abnormalities have been described in patients with renal dysfunction. One final common pathway seems to be endothelial dysfunction. The purpose of this study was to investigate whether decreasing glomerular filtration rate (GFR) is associated with functional abnormalities in coronary flow or in peripheral vasculature in patients with chronic kidney disease (CKD) but without symptomatic coronary artery disease. Methods: Myocardial blood flow was measured at baseline and during dipyridamole-induced hyperaemia (intravenously 0.56 mg/kg body weight in 4 min) by means of positron emission tomography (PET) and oxygen-15-labeled water. The peripheral artery endothelial function was examined by measuring flow-mediated dilatation using ultrasound at rest and during reactive hyperaemia in the brachial artery. Patient demographics are shown in table. Baseline characteristics were similar between the groups, with the exception of use of hypertensive medication by CKD patients, all but one used angiotensin enzyme inhibitor or angiotension receptor blocker. The amount of proteinuria was approximately 0.5 g/day in CKD patients. Diabetic patients were excluded. Results: Baseline myocardial blood flow was significantly higher in CKD (stage 3-5) patients than in healthy controls (p<0.001). The baseline flow was equal in all CKD stages. A singnificant and equal increase in myocardial blood flow was detected in every group after dipyridamole infusion thus leading to equal coronary flow reserve in every group (table) . The peak flow mediated dilatation response (peak FMD %) was highest in healthy controls, 9.6±2.5%. It was significantly lower in CKD patients but didn't differ according to CKD stage (groups 3 to 5: 6.0±5.0% vs. Conclusions: To our knowledge this is the first report of myocardial blood flow measurements using PET techniques in CKD patients. Interestingly our results show that baseline myocardial blood flow is increased in CKD patients compared to healthy controls. The coronary flow reserve is also preserved despite of declining eGFR. However, CKD patients showed impaired endothelial function peripherally. The mecanisms regulating vascular responses in the heart and peripheral vasculature may be different.
SO037 FLUID OVERLOAD AND MALNUTRITION ASSESSED WITH BIOIMPEDANCE SPECTROSCOPY (BIS) ARE STRONG PREDICTORS OF MORTALITY IN HEMODIALYSIS PATIENTS
Introduction and Aims:
Mortality rate of patients receiving Renal Replacement Therapies (RRTs) has remained stable in the last decades. We hypothesized that the adjusted survival probabilities may have improved over time as new patients are getting older and sicker. The effect of dialysis start period on mortality rates was studied in a large cohort of incident RRT patients in Lombardy (northern Italy The propensity score for PD or HD patients was estimated with logistic regression using year of incidence, sex, age, primary kidney disease, known comorbidities (diabetes, ischemic heart disease, heart failure, hypertension, liver disease, stroke, peripheral vascular disease, cancer and pulmonary disease), and region as predictive variables. Patients were classified in blocks balanced according to the propensity score. The survival analysis was repeated stratifying over propensity score blocks. Results: 18841 subjects started RRT in the considered period: 2313 on PD and 16528 on HD. In 5 years overall mortality was lower in PD than in HD (log-rank test: χ 2 = 11.74, p=0.0006), and in the first year PD patients had a significant survival advantage (RR=0.65, 95%CI: 0.57 -0.74). After propensity score stratification, no difference in survival between the two treatments was observed (log-rank test: χ 2 =0.72, p=ns), but the survival advantage in the first year for PD was yet present (RR=0.71, 95%CI: 0.62 -0.81), while a survival disadvantage was observed in the second and in the third year (RR=1.18, 95%CI: 1.00 -1.39 and RR=1.33, 95%CI: 1.09 -1.61 respectively). Conclusions: Our nation-wide findings confirm observational studies performed in other countries. Propensity score adjustment accounts only for observed covariates, thus we may state that, conditioning on age and health status, PD and HD promise the same overall survival. This result emphasizes the selection bias in the choice of renal replacement modality. Other unknown confounders, such as renal residual function, and bias, particularly lead time bias, may account for the differences observed at specified analysis times. Introduction and Aims: Death from cardiovascular causes is the major cause of death in patients with endstage renal failure. While patients with renal failure have a high prevalence of classical coronary risk factors, there is increasing evidence that atherosclerosis, i.e. the evolution and composition of plaques is different in renal compared to non-renal patients. Currently, there is a lack of data concerning the morphological characteristics of vascular structural changes and atherosclerosis in patients with different stages of renal failure. Therefore, the present study compares changes in different vessels obtained at cardiac surgery between patients with early and late stages of renal dysfunction and non-renal control patients. Methods: 50 patients undergoing cardiac bypass surgery were devided into 3 groups:1. patients with S-creatinine <1.3 mg/dl (control group, n=24), 2. patients with moderately elevated S-creatinine (1.3-2.0 mg/dl, early CRF, n=14), 3. patients with established renal failure (S-creatinine >2.0 mg/dl or dialysis treatment, CRF, n=12). A. mammaria int., aorta, small subcutaneous arterioles and V. saphena were analysed using quan-titative morphometry and immunohistochemistry for markers of inflamma-tion (CRP, CD40, CD154, iNOS, eNOS, ICAM, VCAM). Then, univariate analysis and correlation analyses were performed. Results: Media thickness and inflammation score of the A. mammaria int. and aorta was sig. higher in CRF patients than in controls. In contrast, significant inflammation of all vessels and calcification of the aortic media was already present in early CRF. Calcification of the aortic intima and of V. saphena was significantly more pronounced in CRF patients than in and controls. Of note, CaxP product correlated well with markers of inflammation, but not with calcification itself. Conclusions: Early stages of CRF are associated with local upregulation of proinflammatory molecules in the vascular wall and calcification of the aortic media. These findings point to the importance of systemic and local microinflammation in CRF and may shed new light on the possibly overestimated role of the CaxP product for vessel calcification. Introduction and Aims: Previous findings suggest that an auxiliary liver transplantation a few hours before a renal transplantation improves kidney graft survival in patients with multispecific HLA antibodies. To elucidate the mechanisms behind liver-induced graft acceptance we have investigated whether expression of tolerance-inducing genes coincides with graft acceptance and survival in these patients. Methods: DNA microarrays were used to identify genes with altered expression levels in liver and kidney biopsies in one patient undergoing combined auxiliary liver and kidney transplantation. The expression levels of interesting genes, selected by bioinformatics methods, were validated by real-time PCR in samples from eight patients undergoing the same surgical procedure. The gene expression was also correlated to clinical outcome. To confirm that changes in gene expression is mirrored on protein level HPLC was used to detect enzyme-activity in patient sera. Results: Expression of the tolerance-inducing gene indoleamine 2,3-dioxygenase (IDO) in the grafted organs was detected in the microarrays. The expression level of IDO was validated by real-time PCR in samples from 8 patients undergoing the same surgical procedure. IDO mRNA was upregulated 12-fold in the liver graft 4 hours after reperfusion and 90-fold in both liver and kidney after 1 week, whereas IDO-expression in the patient's own liver remained at the limit of detection similar to the values of the pre-transplant biopsies for all organs. Gene expression levels in the liver graft 4 h after reperfusion correlated with clinical outcome. To verify IDO activity, the metabolite kynurenine and substrate tryptophan was measured in patient serum. Enzyme activity was measured as ratio between kynurenine and tryptophan. Preliminary results show an increase in IDO-activity after combined auxiliary liver and kidney transplantation (+102% 24h after transplantation, n=2), whereas IDO-activity decrease 24 h after regular kidney transplantation (-54%, n=5) compared to pre-transplant values. Conclusions: We conclude that IDO is upregulated after auxiliary combined liver and kidney transplantation. This enzyme is tolerance-inducing and its expression correlates with clinical outcome in these patients, indicating a role for it in the liver-mediated acceptance of a renal graft in highly sensitized patients. Results: Renal and splenic amyloidosis was present in all patients on SAP scintigraphy. Coronary disease was identified in 60% of cases, and systemic vascular disease in 50%. Vascular atheroma excised at carotid endarterectomy in one case, contained abundant amyloid in the intima and thrombus, that on molecular analysis was wholly derived from variant fibrinogen. Cardial biopsies in a small number of E526V patients and in R554L, revealed amyloid deposits in the myocardium and blood vessels. Autonomic dysfunction was identified in 10 cases. Eight patients were declined LKT due to cardiovascular risks, 3 are listed for LKT, and the R554L patient is assessed for triple heart/liver/kidney transplant. Eight patients received LKT in the past 11 years, 6 of whom are well with good dual graft function at median fol-up of 43.7 (10-132) months. Biochemical studies confirmed that variant fibrinogen was eliminated from the plasma following LKT, and SAP scintigraphy has shown regression of visceral amyloid. Two long-term haemodialysis patients died postoperatively with dysautonomia and cardiovascular events. Conclusions: AFib is a systemic amyloid disease with visceral, vascular, and neurological involvement. Combined liver and kidney transplantation in patients with AFib and ESRD eliminates the sole, hepatic source of variant fibrinogen, prevents amyloid recurrence, and facilitates regression of systemic amyloid deposits. Cardiovascular disease is common in AFib; we are investigating the significance of amyloid deposition in the heart and vascular walls, along with the observed association of AFib with arterial disease. Introduction and Aims: MICA antibodies were associated with organ transplant rejection, having a strong homology with the HLA class I, but it has no role in antigen presentation. The objective of the study was to identify factors that were independently associated with the more presence of Anti-MICA antibodies in the graft loss of the renal transplant (RT). Methods: A cross-sectional and a prospective study of RT patients were done in our hospital. Anti-MICA antibodies were tested by x-MAP Technology (LuminexÒ). Clinical variables: age and sex of donor and recipient, donor cause of death, recipient kidney disease, previous transplants, transfusions, preformed cytotoxic antibodies, HLA mismatches, cold ischemia time (CIT, recoded in <12 hours, between 13 and 19 hours, and >20 hours), renal function tested by serum creatinine (scr) and creatinine clearance (cCl), complications (delayed graft function (DGF), nephrotoxicity, acute rejection (AR), posttransplant diabetes mellitus (PTDM), infections, immunosuppressive drugs. Results: A total of 96 RT were followed-up 5 years. 81% had first RT and 31 (32%) of them had anti-MICA antibodies. Donor: 41±17 years, 51% cerebral deceased of hemorragia/isquemia. Recipient: 48±11 years, 63% male, kidney disease: glomerulonephritis: 37%, polycystic kidney diseases: 13%, vascular nephropathy: 10%, tubulointerstitial nephritis: 8%, diabetes mellitus: 8%. CIT: 17±4 hours. Immunosuppression drugs: 28% induction therapy; CsA from the beginning 63%, Tacrolimus 43%, MMF 66%, Azathioprine 25%. Complications: 22% DGF; 19% nephrotoxicity; 12.5% AR; 12% PTDM. There were differences in the existence of previous RT (the patients with anti-MICA antibodies received more transplants 10/21 vs 8/57, p=0.026), in the grafts loss (the patients with anti-MICA antibodies lost more 5/26 RT vs 1/64, p=0.013) and CIT (p=0.003). The logistic regression was developed with the statistical significant variables in the univariate model to identify the variables that have independent effect on having anti-MICA antibodies. Introduction and Aims: We aimed to understand the influence of peritubular capillary (PTC) and vascular macrophage infiltration on steroid response and renal allograft outcomes after acute rejection (AR) episodes. Methods: Seventy-nine patients with biopsy-proven AR in their first year after transplantation were included in the study. Thirty patients with normal first year renal allograft biopsies were also included in the study and used as a control group. All biopsies were C4d negative. Immunohistochemically we assessed the degree of macrophages (CD68) and HLA-DR-positive infiltrating cells in PTC's, glomeruli, and on vascular walls and tubules. In addition HLA-DR expression of PTC's was also evaluated. The decreasing intensity of peritubular capillary HLA-DR (PTC-DR) expression was accepted as the increasing degree of the destruction of PTC. Results: Compared to control group AR cases showed significantly higher degree of macrophage and HLA-DR positive inflammatory cell infiltration in PTC's, glomeruli, and on vascular walls and tubules (P<0.001 for all). PTC destruction was significantly higher in AR cases than control group (p<0.001). PTC, glomerular and vascular macrophage infiltration showed significant correlation with PTC destruction and steroid response (p<0.001 for all). Severity of PTC destruction with accompanying higher degrees of macrophage infiltration in PTC's, glomeruli and on vascular walls caused unresponsiveness to steroid therapy (p<0.001) and poor graft outcome (p<0.001). Five-year graft survival was 95%, 37% and 22% for cases with grade 0, 1 and 2 PTC macrophage infiltration respectively (P<0.001). In addition five-year survival was 80%, 36% and 1% for cases with grade 0, 1 and 2 vascular macrophage infiltration respectively (p<0.001). Conclusions: In conclusion peritubular capillary and vascular macrophage infiltration are important predictors of steroid response and renal outcome following acute rejection in cases whom especially had negative C4d.
SO043 INTIMA AND MEDIA THICKENING, CALCIFICATION AND INFLAMMATION IN PATIENTS WITH EARLY AND LATE STAGES OF RENAL FAILURE
SO045
HEREDITARY FIBRINOGEN A α ALPHA-CHAIN AMYLOIDOSIS: PHENOTYPIC CHARACTERIZATION AND OUTCOME OF COMBINED LIVER AND KIDNEY TRANSPLANTATION
SO046 IDENTIFICATION OF THE FACTORS THAT MIGHT PLAY A ROLE IN THE EXISTENCE OF ANTI-MICA ANTIBODIES IN THE GRAFT LOSS OF THE RENAL TRANSPLANT
Introduction and Aims:
Use of angiotensin receptor blockers (ARBs) and beta blockers (BBs) has been associated with lower mortality in recent studies of prevalent HD patients, but there is concern that their use may hasten loss of residual renal function (RRF) among incident HD patients. Methods: We studied 8,176 patients entering the DOPPS I and II studies within 30 days of starting HD. This sample included >400 facilities in 12 countries. Patients were classified as taking one or more AHAs by class at study entry: BB, renin angiotensin system [RAS] inhibitors (ARB or ACE Introduction and Aims: Toll-like receptors (TLRs), as pathogen recognition receptors, classically detect evolutionary conserved danger signals, e.g. structural motifs of bacterial or viral origin. TLRs are known to be predominantly expressed by leukocytes belonging to the innate immune system. However, previously we could show functional expression of TLR3 by mesangial cells, activation of TLR3 led to an induction of proinflammatory chemokines (Am J Path 2006). The aim of the present study was to examine the TLR expression pattern of podocytes under basal conditions, or after treatment with proinflammatory cytokines (IL-1β, IFN-γ, TNF-α), respectively. Thereafter, TLR-dependent chemokine expression was analyzed after stimulation of the cells with potential exogenous or endogenous TLR ligands. To prove specificity of TLR-mediated effects siRNAs blocking TLR expression were developed. Methods: In murine podocytes we investigated the expression of TLR1-9 and 11 under basal conditions as well as after incubation with IL-1β, IFN-γ and TNF-α alone or in combination by quantitative real-time PCR. Dependent on the availability of specific antibodies TLR expression was analyzed on protein level too. Subsequently chemokine expression was determined under basal and stimulatory conditions for different incubation periods (2h to 48h), in the absence or presence of TLR-specific siRNA. Results: Under basal conditions, a significant expression of TLR1 to 7, 9 and 11 and a low expression of TLR8, 12 and 13 was detected. After incubation of podocytes with a combination of IL-1β, IFN-γ and TNF-α, a different expression pattern was detectable. Examination of chemokine expression after treatment with the exogenous TLR-ligands peptidoglycan, poly I:C RNA or Lipid A, respectively, revealed a significant upregulation of the chemokines CCL2, CCL5, CCL7, CXCL1, and CXCL5. Specificity of TLR signalling could be proven by downregulation of single TLRs via
